Yes, Cyberknife is an indicated treatment for early prostate cancer and is covered by Medicare and other insurance companies.
Patients with low or intermediate risk prostate cancer with a prostate gland size of less than 100 cubic centimeters are ideal candidates for Cyberknife prostate therapy.
It is as effective as the standard course of radiation treatment.
Most patients experience minimal or mild side effects from a Cyberknife treatment session. Some patients do experience mild urinary and rectal irritation but no nausea or fatigue.
No, patients do not feel anything from the radiation during treatment.
5 treatments will accomplish the goal (1 every other day).
Cyberknife sessions range between 30 minutes to an hour.
Once you have decided to have the treatment, you can expect completion in approximately one month. This includes time for consultation, preparation, treatment and follow-up.
The Cyberknife requires that four gold fiducial markers are implanted into the prostate by the urologist, then a special CAT scan is taken with the patient in the treatment position so the radiation oncologist can develop a treatment plan.
Within a matter of days.
Yes - it is not necessary to be medicated during treatment and Cyberknife does not result in the kind of fatigue experienced by patients undergoing routine radiation treatment. However, should you request a mild sedative to relax you should not drive until you obtain approval from your doctor.
No, the FDA approved Cyberknife for treatment of a variety of organs (including prostate) in 2001. It is endorsed by Medicare and the American Society for Therapeutic Radiation Oncology (ASTRO).